Summary
Regeneron Pharmaceuticals, Inc. (REGN) has filed an 8-K report on July 6, 2026, providing a preliminary update on its expected financial results for the second quarter of 2026. The company anticipates a pre-tax acquired in-process research and development (IPR&D) charge of approximately $127 million. This charge is primarily related to up-front and opt-in payments made under various collaboration and licensing agreements. The estimated impact of this acquired IPR&D charge is a reduction of approximately $1.00 per diluted share on both Generally Accepted Accounting Principles (GAAP) and non-GAAP net income for the second quarter. Regeneron cautions that these are preliminary estimates and subject to change as financial closing procedures are completed, and actual results may differ. Investors should note that IPR&D charges are inherently unpredictable due to the uncertain nature of future collaborations and development milestones.
Key Highlights
- 1Regeneron anticipates a pre-tax acquired IPR&D charge of approximately $127 million for Q2 2026.
- 2This charge is expected to reduce both GAAP and non-GAAP net income per diluted share by approximately $1.00.
- 3The IPR&D charge is associated with collaboration and licensing agreements, including up-front and opt-in payments.
- 4The company emphasizes that these are preliminary, unaudited estimates and actual results may vary.
- 5Regeneron does not forecast IPR&D charges due to their inherent uncertainty in timing and magnitude.
- 6The filing includes standard forward-looking statement disclaimers, noting risks and uncertainties.
- 7A reconciliation of non-GAAP financial measures to GAAP is provided, highlighting management's use of non-GAAP data for operational assessment.